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Abstract 
Background: Laboratory studies suggest that the clotting cascade is activated in fibrotic lungs. Since 
humans vary in their tendency to clot due to a variety of inherited or acquired defects, we investigated 
whether a prothrombotic state increases the chance of developing idiopathic pulmonary fibrosis (IPF) 
and/or worsens prognosis of IPF. 
Methods:  We recruited 211 incident cases of IPF and 256 age and sex matched general population 
controls and collected data on medical history, medication, smoking habit, blood samples, as well as 
lung function and high resolution computed tomography scans done as part of routine clinical care. A 
prothrombotic state was defined as the presence of at least one inherited or acquired clotting defect 
or marker of fibrinolytic dysfunction.  We used logistic regression to quantify the association between 
a prothrombotic state and IPF adjusted for age, sex, smoking habit and highly sensitive C Reactive 
Protein. Cox regression was used to determine the influence of a prothrombotic state on survival. 
Results: Cases were more than four times more likely to have a prothrombotic state compared to 
controls (OR 4.78, 95% CI: 2.93 to 7.80; p<0.0001). Cases with a prothrombotic state were also likely 
to have more severe disease (FVC <70% predicted) at presentation (OR 10.79, 95% CI: 2.43 to 47.91) 
and had a three-fold increase risk of death (HR 3.26, 95% CI: 1.09 to 9.75).   
Conclusion:  People with IPF are more likely to have a prothrombotic state than general population 
controls and the presence of a prothrombotic state has an adverse impact on survival.  
(250 words) 
  
Key messages 
What is the key question? 
 Are people with idiopathic pulmonary fibrosis (IPF) more likely to have a prothrombotic state than 
general population controls, and does this alter survival amongst people with IPF? 
What is the bottom line? 
 People with IPF were almost five times more likely to have at least one inherited or acquired clotting 
defect compared to general population controls, and a prothrombotic state in people with IPF was 
associated with a three-fold increase risk of death. 
Why read on? 
 This is the largest population based study to investigate the association between the increased 
tendency to clot and IPF, which has enabled detailed investigation of the association between 
individual clotting defects and IPF, disease severity at presentation and survival.  
 
 
 
 
 
 
 
 
 
Introduction 
Idiopathic pulmonary fibrosis (IPF) is an important public health problem, with a disease burden of 
similar magnitude to ovarian and renal cancers in terms of incidence and survival.[1-3] Although there 
have been recent insights into the pathogenesis of IPF,[4] the underlying aetiology of the disease 
remains poorly understood and there are currently no treatments which improve survival.  
Laboratory studies and animal models have suggested that activation of the clotting cascade occurs in 
fibrotic lungs.[5-7] Epidemiological data to support this hypothesis come from a large study using UK 
primary care data demonstrating that people with IPF are at increased risk of having a venous 
thromboembolic event (VTE), even before the diagnosis of pulmonary fibrosis was made.[8] This 
association between pulmonary fibrosis and VTE has also been suggested in studies using a large 
Danish registry[9] and American death certificate data.[10]  A clinical trial in Japan also indicated that 
anticoagulation in individuals with severe IPF may improve survival.[11] A recent placebo controlled 
trial of warfarin for IPF was stopped early due to the excessive number of deaths in the warfarin arm 
that were not due to complications of anticoagulation,[12] raising the possibility that manipulation of 
the clotting cascade using traditional anticoagulation drugs may accelerate rather than treat the 
disease process.  
A significant proportion of the general population are at an increased risk of thrombotic episodes due 
to a combination of inherited and acquired defects in the clotting cascade.[13, 14] The commonest 
coagulopathies for people living in the UK are Factor V Leiden mutation and elevated factor VIII levels. 
The aim of our study was to use this natural experiment to investigate the association between clotting 
dysfunction and IPF and investigate if it influenced its natural history. We conducted a case–control 
study of incident cases of IPF to investigate if people with IPF were more likely to have a prothrombotic 
state than general population controls, and if this altered subsequent survival.  
Methods 
Identification and recruitment of cases and controls 
We identified potential incident cases of IPF seen at five teaching and eight district general hospitals 
in the Greater Trent region and Wales between January 2010 and February 2012 (see Figure 1). 
Controls were frequency matched on age and sex, and consisted of people in the general population 
that did not have a diagnosis of IPF, and were identified from 10 primary care centres involved in the 
UK Primary Care Research Network in the Greater Trent Region.  Ethical approval for the study was 
granted by the Nottingham Research Ethics Committee (REC reference 09/H0403/59) and research 
and development approval obtained for each participating centre. 
Data collection 
Cases and controls were invited to participate in the study by their respiratory physician or general 
practitioner. All participants were sent a questionnaire asking for details of medical history, 
medication and smoking habit and had a venous blood sample taken. We also collected results of 
pulmonary function tests conducted according to the ATS/ERS task force guidelines [15-17] and HRCT 
scans done as part of routine care for the cases. All participants were tagged with the NHS Information 
Centre to enable us to collect data on subsequent mortality and cause of death. 
Laboratory analysis 
 Laboratory testing was conducted for inherited clotting defects including Factor V Leiden mutation, 
prothrombin G20210A mutation, methylenetetrahydrofolate reductase (MTHFR) deficiency, 
antithrombin III deficiency, elevated factor VIII levels, protein C and free protein S deficiency, acquired 
clotting defects including lupus anticoagulant and anticardiolipin antibodies and markers of 
fibrinolysis including D Dimer levels and clot lysis times. All laboratory analyses were performed in the 
laboratories at Nottingham University Hospitals NHS Trust in accordance with standard clinical 
laboratory practice. 
Statistical Analysis 
We only included cases with diagnoses of definite or probable UIP in the main analyses. Our main 
exposure was a prothrombotic state, which was a composite binary variable, defined as having at least 
one of the measured inherited or acquired clotting abnormalities.  Logistic regression was used to 
generate odds ratios for the association between a prothrombotic state and IPF adjusting for age 
category and sex, which was our baseline statistical model. We investigated the association of the 
individual clotting defects stated above and IPF, by replacing our composite prothrombotic state 
variable with the individual clotting defect in turn. We repeated the analyses, also adjusting for 
smoking habit and highly sensitive C Reactive Protein (hsCRP) as potential confounding variables. 
Using the same baseline and multivariate models, we looked for an exposure-response signal in terms 
of the absolute number of clotting defects present and IPF, and  a quantitative analysis on the most 
common clotting defects and markers of clotting dysfunction and IPF after excluding individuals 
currently on warfarin. We conducted a separate analysis among the cases to determine if a 
prothrombotic state was associated with pulmonary function indices of disease severity. The main 
analyses were repeated stratifying cases by radiological diagnoses of definite or probable Usual 
Interstitial Pneumonia (UIP). Cases with fibrotic non-specific interstitial pneumonitis (NSIP) and 
unclassified fibrotic lung disease were analysed separately. Cox regression modelling was used to 
investigate if a prothrombotic state was associated with increased mortality among people with IPF 
using the same statistical models. We assigned the date participants gave consent to enter the study 
as the start date, and the date of the death or last data collection as the stop date. We assessed the 
impact of the same coagulation defects, and the association between absolute number of clotting 
defects present on survival. The analyses were repeated adjusting for baseline Forced Vital Capacity 
(FVC) and Diffusion Capacity (DLCo) per cent predicted. Proportional hazard assumptions were 
checked using log-log plots and scaled Schoenfeld residuals. 
The study was designed to include 244 cases of IPF and 244 controls frequency matched to age and 
sex to provide more than 90% power to detect an odds ratio of 2 or greater on assumption that the 
prevalence of thrombophilia in the control group was 20%. STATA version 11.0 (Texas) was used for 
all statistical analyses and hypothesis testing. 
 
Figure 1: Flow chart depicting recruitment of incident cases of IPF and general population controls 
 
 
 
 
 
 
 
Results 
Case–control analysis 
We recruited 306 incident cases of physician diagnosed idiopathic pulmonary fibrosis (IPF) and 256 
controls during the study period. After central review of high resolution computed tomography (HRCT) 
scans by two thoracic radiologists (KP and MK), we had 110 cases of definite UIP and 101 cases with 
probable UIP (see Table 1). Only these 211 cases of definite or probable UIP were included in 
subsequent analyses. The mean age of cases with definite or probable UIP was 73.7 years (standard 
deviation [SD] 8.5 years) and the cases were predominantly male. Cases were more likely than controls 
to have a previous thromboembolic event, history of ischemic heart disease, to be currently or 
previous on aspirin and/or warfarin and have a hsCRP level of above 3 mg/ml (see Table 2). 
 A prothrombotic state was more than four times more common in the cases compared to controls in 
both our baseline (Odds Ratio [OR] 4.38, 95% Confidence Interval [CI]: 2.85 to 6.74; p<0.0001) and our 
multivariate models. (OR 4.78, 95% CI: 2.93 to 7.80; p<0.0001) (see Table 3). After excluding 
individuals currently on warfarin, cases (n=194) were more than seven times more likely than controls 
(n=250) to have factor VIII levels above 165 IU/dL in both the baseline (OR 7.20, 95%CI: 4.65 to 11.18; 
p<0.0001) and multivariate models (OR 7.02, 95%CI: 4.27 to 11.51; p<0.0001).  There was no effect 
modification by age or sex on any of our findings. 
Exposure-response analyses, association with disease severity and radiological diagnosis 
Cases were more than five times more likely to have two or more clotting defects compared to 
controls in both baseline (OR 7.66, 95% CI: 2.81 to 20.88) and multivariate (OR 5.85; 95% CI: 2.05 to 
16.81) models. We found evidence of an exposure-response signal with increasing levels of Factor VIII, 
D Dimer and Clot Lysis Times (see Table 4) 
Pulmonary function test results at time of diagnosis were available for 200 out of 211 (95%) individuals 
of our IPF cohort. The mean forced vital capacity (FVC) per cent predicted was 84.4 (SD: 19.6) and 
mean diffusion capacity (DLco) per cent predicted was 45.4 (SD: 16.4).  We found an association 
between an increased tendency to clot and severity of IPF at presentation (see Table 5).  
The increased tendency to clot was marginally higher among cases with definite UIP (n=110) in the 
baseline (OR 5.77, 95% CI: 3.21 to 10.34; p<0.0001) and multivariate models (OR 6.31, 95% CI: 3.32 to 
11.97; p<0.0001). Cases with probable UIP (n=101) had a three-fold increase in tendency to clot in 
both baseline (OR 3.37, 95% CI: 1.98 to 5.74; p<0.0001) and multivariate  models (OR 3.49, 95% CI: 
1.90 to 6.40; p<0.0001). We also found that the increased tendency to clot was also present in the 
subset of cases with fibrotic non-specific interstitial pneumonitis (NSIP) (n=28) in the baseline (OR 
4.74, 95% CI: 1.69 to 13.33; p=0.001) and multivariate models (OR 5.71, 95%CI: 1.82 to 17.97; p=0.001) 
or unclassifiable fibrotic lung disease(n=67) in the baseline(OR 4.29, 95% CI: 2.22 to 8.27; p<0.0001) 
and multivariable models (OR 4.05, 95% CI: 1.97 to 8.32; p=0.0001). 
Survival analysis 
The median follow-up for people with definite or probable UIP after the start date was 1.14 years. 
During this period, 56 out of 211 (26.5%) individuals with IPF died. The overall mortality rate of the 
cohort was 215.0 (95% CI 165.5 to 279.4) per 1000 person-years.  A prothrombotic state increased 
mortality by three times among people with IPF after adjusting for age and sex (Hazard Ratio [HR] 
3.38, 95% CI: 1.22 to 9.21; p=0.006) and after adjusting for age, sex, smoking habit and hsCRP (HR 
3.45, 95% CI: 1.15 to 10.65; p= 0.007), with a four-fold increase risk of death among cases with two or 
more clotting defects (see Table 6, Figure 2). The increased mortality was unchanged after adjusting 
for baseline FVC and DLco. (HR 3.50, 95% CI: 1.09 to 9.75; p=0.015). Current anticoagulation with 
warfarin or hsCRP level greater than 3mg/ml had no association with survival (see Table 7). There was 
no evidence of effect modification by age or sex, or that the proportional hazards assumptions for our 
final models were not met (p=0.425; scaled Schoenfeld global test). 
Table 1: Radiological diagnoses within the cohort of physician diagnosed idiopathic pulmonary fibrosis 
(IPF) 
Radiological 
diagnosis 
Number of 
cases (%) 
Number of 
men (%) 
Mean age at 
diagnosis 
(years) 
Mean FVC % 
predicted 
Mean TLCO % 
predicted 
Definite usual 
interstitial 
pneumonia 
110 (36) 86 (78) 74.2 (8.3) 83.9 (17.9) 43.4 (14.5) 
Probable usual 
interstitial 
pneumonia 
101 (33) 72 (71) 72.1 (8.6) 86.7 (17.2) 46.8 (15.2) 
Fibrotic non-specific 
interstitial 
pneumonitis 
28  (9) 14 (50) 71.3 (7.4) 83.6 (19.3) 45.4 (13.9) 
Unable to classify 67 (22) 44 (66) 71.6 (8.8)   82.0 (25.5) 46.9 (21.7) 
 
Table 2: Demographics of incident cases of IPF and general population controls  
Characteristic  Cases 
(n=211)  
Controls 
(n=256)  
Odds Ratio (95% CI)* 
Mean age (standard 
deviation) 
 73.7 (8.5) 70.9 (9.0)  
Number of men (%)  158 (74.9) 189 (73.8)  
Smoking habit (%) Never smoked 59 (28.0) 113 (44.1) 1.00 
 Ex-smokers 135 (64.0) 119 (46.5) 2.32 (1.52-3.55) 
 Current smokers 17 (8.0) 24 (9.4) 1.73 (0.83-3.62) 
Previous venous 
thromboembolic event (%) 
 23 (10.9) 15 (5.9) 1.65 (0.82-3.30) 
Previous ischemic heart 
disease (%) 
 66 (31.3) 43 (16.8) 1.97 (1.25-3.11) 
Anticoagulant status (%) Never been on 
warfarin 
182 (86.3) 239 (93.4) 1.00 
 Previously been on 
warfarin 
12 (5.7) 11 (4.3) 1.23 (0.92-2.94) 
 Currently on 
warfarin 
17 (8.1) 6 (2.3) 2.96 (1.12-2.79) 
Anti-platelet treatment (%) Never been on 
aspirin 
104 (49.3) 157 (61.3) 1.00 
 Previously been on 
aspirin 
31 (14.7) 20 (7.8) 2.05 (1.08-3.88) 
 Currently on 
aspirin 
79 (30.9) 76 (36.2) 1.08 (0.71-1.66) 
Highly sensitive C Reactive 
Protein category (%) 
<1 mg/ml 20 (9.5) 70 (27.3) 1.00 
 1-3 mg/ml 50 (23.7) 111 (43.4) 1.47 (0.79-2.75) 
 >3 mg/ml 137 (64.9) 63 (24.6) 8.13 (4.42-14.94) 
*All odds ratios are adjusted for age and sex 
Table 3: Association between individual clotting defects and IPF 
Clotting defect Prevalence in 
cases   
(n=211) (%) 
Prevalence 
in controls  
(n=256) (%) 
Odds ratio* 
(95% CI) 
Odds ratio# 
(95% CI) 
No clotting defects 41 (19.4) 137 (53.5) 1.00 1.00 
Prothrombotic state& 170 (80.6) 119 (46.5) 4.38 (2.85-6.74) 
p<0.0001 
4.78 (2.93-7.80) 
p<0.0001 
Prothrombin gene 
mutation 
10 (4.7) 6 (2.3) 1.74 (0.61-5.02) 1.73 (0.52-5.72) 
Factor V Leiden mutation 5 (2.4) 11 (4.3) 0.49 (0.16-1.49) 0.44 (0.13-1.43) 
MTHFR homozygous 
gene mutation 
21 (10.0) 24 (9.4) 1.08 (0.55-2.11) 1.07 (0.51-2.28) 
Antithrombin III 
deficiency^ 
7 (3.3) 2 (0.8) 5.54 (1.06-29.02) 5.20 (0.92-29.37) 
Elevated factor VIII 
levels>165 iu/dL 
129 (61.1) 45 (17.6) 7.21 (4.65-11.18) 
p<0.0001 
7.02 (4.29-11.59) 
p<0.0001 
Free Protein S <65 IU/dL 23 (10.9) 12 (4.7) 2.12 (1.00-4.48) 2.06 (0.90-4.74) 
Protein C <64 IU/dL 15 (7.1) 6 (2.3) 2.90 (1.07-7.90) 2.66 (0.89-8.00) 
Clot lysis time>240 mins  163 (77.3) 170 (66.4) 1.87 (1.21-2.88) 1.60 (0.98-2.83) 
D Dimer>180 IU/dL 115 (54.5) 100 (39.1) 1.72 (1.16-2.54) 1.69 (1.09-2.62) 
Lupus anticoagulant 4 (1.9) 2 (0.8) 2.90 (0.48-17.35) 5.38 (0.75-38.33) 
Anticardiolipin IgG 
antibodies 
4 (1.9) 0 (0) 0 0 
 
*Odds ratios are adjusted for age category and sex   #Odds ratios are adjusted for age category, sex, smoking habit and hsCRP 
category 
&Prothrombotic state is a composite binary variable  where at least a single clotting defect was detected on laboratory testing 
^Antithrombin deficiency was defined as levels below 2 standard deviations from the mean value of the general population 
controls 
 
 
 
 
 
 
 
 
Table 4: Number of clotting defects and exposure-response relationship of common clotting 
abnormalities~ 
  Prevalence in 
cases 
(n=194) (%)  
Prevalence in 
controls 
(n=250) (%) 
Odds ratio* (95% CI) Odds ratio# (95% CI) 
Number of 
clotting 
defects^ 
0 41 (21.1) 134 (53.6) 1.00 1.00 
 1 116 (59.8) 99 (39.6) 3.53 (2.25-5.57) 3.84 (2.31-6.40) 
 2 or 
greater 
37 (19.1) 17 (6.8) 6.31 (3.16-12.60) 
p for trend <0.0001 
5.74 (2.67-12.34) 
p for trend <0.0001 
Factor VIII 
level (IU/dl) 
≤165 82 (38.9) 211 (82.4) 1.00 1.00 
 166-250 107 (50.7) 41 (16.0) 6.54 (4.14-10.31) 6.75(4.04-11.27) 
 ≥251 22 (10.4) 4 (1.6) 14.21 (4.65-43.40) 
p for trend<0.001 
 9.43 (2.82-31.52)  
p for trend<0.001 
Free Protein 
S (IU/dL) 
≥66 186 (95.8) 243 (97.2) 1.00 1.00 
 56-65 5 (2.6) 4 (1.6) 1.55 (0.39-6.19) 1.18 (0.24-5.80) 
 ≤55 3 (1.6) 3 (1.2) 1.16 (0.21-6.49) 
p for trend=0.662 
1.26 (0.21-7.56) 
p for trend=0.701 
D Dimer ≤180 80 (41.2) 151 (60.4) 1.00 1.00 
 181-
1000 
101 (52.1) 89 (35.6) 1.91 (1.26-2.90) 1.77 (1.11-2.81) 
 ≥1001 13 (6.7) 10 (4.0) 2.51 (1.02-6.19) 
p for trend=0.003 
3.70 (1.33-10.33) 
p for trend=0.003 
Clot lysis 
time (mins) 
≤240 46 (23.7) 85 (34.0) 
 
1.00 1.00 
 241-340 106 (54.6) 152 (60.8) 1.40 (0.89-2.21) 1.17 (0.70-1.96) 
 ≥341 42 (21.7) 13 (5.2) 6.80 (3.20-14.44) 
p for trend<0.001 
5.64 (2.48-12.85) 
p for trend<0.001 
~ Analyses performed after exclusion of individuals currently on warfarin 
*Odds ratios adjusted for age category and sex     #Odds ratios adjusted for age category, sex, smoking status and hsCRP 
category                
^ The sum of the number of individual clotting defects found on laboratory testing. 
 
 
 
 
 
 
 
 
Table 5: The risk of a prothrombotic state^ in people with IPF stratified by pulmonary function indices 
Pulmonary function 
indices 
  Number of 
cases (%) 
(n=211) 
Odds ratio (95% 
CI)* 
Odds ratio (95% 
CI)# 
% predicted FVC  ≥101 36 (17.1)  1.00 1.00 
 86-100 53 (25.1) 1.84 (0.71-4.76) 2.10 (0.76-5.81) 
 71-85 68 (32.2) 3.48 (1.30-9.30) 4.04 (1.43-11.37) 
 ≤70 43 (20.4) 9.04 (2.24-36.43) 
p for trend=0.536 
10.79 (2.43-47.91) 
p for trend=0.610 
 Missing values 10 (5.2) - - 
% predicted DLco ≥60 26 (12.3) 1.00 1.00 
 46-59 59 (28.0) 2.17 (0.77-6.17) 3.37 (1.09-10.43) 
 31-45 82 (38.9) 3.77 (1.32-10.79) 6.25 (1.95-19.99) 
 ≤30 24 (11.4) 1.80 (0.51-6.37) 
p for trend=0.124 
2.81 (0.72-10.94) 
p for trend=0.152 
 Missing values 20 (9.5) - - 
*Odds ratios adjusted for age category and sex          #Odds ratios adjusted for age category, sex, smoking and hsCRP category                   
^A prothrombotic state is a composite binary variable where at least a single clotting defect was present on laboratory testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Cox regression modelling of individual clotting defects and survival in the IPF cohort 
Clotting defect Number 
of 
deaths 
(n=56) 
Person 
years 
Crude Mortality 
rate (95% CI) 
per 1000 person 
years 
Hazards Ratio*  
(95% CI) 
Hazards Ratio#  
(95% CI) 
No clotting 
defects 
4 53.5 74.7  (28.1-
199.1) 
1.00 1.00 
Prothrombotic 
state& 
52 206.9 251.3 (199.5-
329.8) 
3.38 (1.22-9.41) 
p=0.006 
3.45 (1.21-9.82) 
p=0.007 
Prothrombin 
gene mutation 
3 10.6 282.3 (91.0-
875.18) 
3.88 (0.84-17.85) 4.12 (0.87-19.48) 
Factor V Leiden 
mutation 
2 5.2 383.5 (95.9-
1533.3) 
4.77 (0.85-26.85) 4.83 (0.83-28.14) 
MTHFR 
homozygous 
gene mutation 
7 23.1 302.5 (144.2-
634.5) 
3.85 (1.11-13.34)  3.95 (1.10-14.15) 
Antithrombin III 
deficiency^ 
3 6.6 453.0 (146.1-
1404.5) 
5.59 (1.22-25.59) 5.73 (1.22-26.81) 
Elevated Factor 
VIII>165 IU/dl 
41 155.6 263.53 (194.0-
357.9)  
3.52 (1.25-9.88) 3.56 (1.24-10.20) 
Free protein S 
<65 IU/dl 
12 27.7 433.1 (246.0-
762.6) 
5.56 (1.77-17.44) 6.10 (1.88-19.78) 
Protein C <64 
IU/dL 
6 17.8 337.2 (151.5-
750.6) 
3.92 (1.09-14.07) 4.37 (1.18-16.15) 
Clot lysis 
time>240 mins 
46 202.7 227.0 (170.0-
303.0) 
3.63 (1.30-10.16) 3.67 (1.28-10.53) 
D Dimer>180 
IU/dl 
35 135.7 257.8 (185.1-
359.1) 
3.77 (1.33-10.71) 3.69 (1.27-10.76) 
Lupus 
anticoagulant 
1 6.9 144.9 (20.4-
1028.9) 
1.64 (0.18-14.93) 1.41 (0.14-14.03) 
Anticardiolipin 
IgG antibodies 
2 3.8 530.9 (132.8-
2122.7) 
6.23 (1.11-35.09) 6.55 (1.06-40.32) 
1 clotting 
defect present~ 
30 143.3 209.4 (146.4-
299.4) 
2.91 (1.02-8.30) 2.95 (1.01-8.63) 
2 or more 
clotting defects 
present~ 
22 63.6 345.9 (227.7-
525.3) 
4.35 (1.49-12.73) 
p for trend=0.003 
4.76 (1.56-14.50) 
p for trend=0.003 
 
*Hazards ratios adjusted for age category and sex             #Hazards ratios adjusted for age category, sex, smoking habit and 
hsCRP category 
&Prothrombotic state is a composite binary outcome where at least a single clotting defect was detected on laboratory 
testing 
^Antithrombin deficiency was defined as levels that lay below 2 standard deviations from the mean value of the general 
population controls 
~ The sum of the number of individual clotting defects detected on laboratory testing         
Table 7: Association between demographic characteristics and survival in the IPF cohort 
Demographic 
feature 
 Number 
of 
deaths 
(n=56) 
Person 
years 
Crude mortality 
rate (95% CI) 
Hazards Ratio~ 
(95% CI) 
Hazards Ratio% 
(95%CI) 
Sex Female 13 67.1 193.8 (112.5-
333.8) 
1.00 1.00 
 Male 43 193.4 222.4 (164.9-
299.9) 
1.17 (0.63-2.18) 
p=0.615 
1.16 (0.62-2.16) 
p=0.622 
Age category 
(years) 
<65 7 35.1 199.3 (95.0-
418.0) 
1.00 1.00 
 
 65-69 8 47.2 169.4 (85.7-
338.7) 
0.78 (0.28-2.15) 0.77 (0.26-2.12) 
 70-74 11 57.5 191.4 (106.0-
345.6) 
0.92 (0.35-2.38) 0.91 (0.35-2.36) 
 75-79 19 67.2 282.7 (180.3-
443.3) 
1.25 (0.52-2.98) 1.24 (0.52-2.96) 
 80-84 4 32.2 124.3 (46.6-
331.1) 
0.56 (0.16-1.93) 0.56 (0.16-1.93) 
 ≥85 7 21.2 330.1 (157.4-
692.5) 
1.57 (0.55-4.50) 
p for trend=0.487 
1.54 (0.54-4.43) 
p for trend=0.492 
% predicted 
FVC 
≥101 8 42.8 186.8 (93.4-
373.5) 
1.00 1.00 
 86-100 10 71.3 140.2 (75.4-
260.5) 
0.68 (0.27-1.74) 0.73 (0.28-1.89) 
 71-85 17 89.5 190.0 (118.1-
305.6) 
0.88 (0.38-2.06) 0.90 (0.38-2.14) 
 ≤70 17 45.9 370.4 (230.2-
595.8) 
1.66 (0.77-3.87) 
p for trend=0.524 
1.77 (0.72-4.36) 
p for trend=0.588 
 Missing 
values 
4 - - - - 
% predicted 
DLco 
≥60 2 34.4 58.1 (14.5-
232.4) 
1.00 1.00 
 46-59 8 24.4 94.7 (47.3-
189.2) 
1.50 (0.32-7.05) 1.54 (0.33-7.30) 
 31-45 30 97.7 307.1 (214.7- 
439.2) 
4.72 (1.12-
19.77) 
5.56 (1.31-
23.60) 
 ≤30 8 24.4 327.4 (163.7-
654.7) 
5.68 (1.20-
26.88) 
p for trend=0.409 
6.27 (1.31-
30.06) 
p for trend=0.353 
 Missing 
values 
8 - - - - 
Anticoagulant 
status 
Never 
been on 
warfarin 
48 224.1 214.2 (161.4-
284.2) 
1.00 1.00 
 Previously 
on 
warfarin 
1 15.9 63.1 (8.9- 447.6) 0.28 (0.04-1.99) 0.29 (0.04-2.28) 
 Currently 
on 
warfarin 
7 20.4 342.5 (163.3-
718.5) 
1.32 (0.60-2.94) 
p=0.827 
1.25 (0.56-2.79) 
p=0.865 
 
Smoking habit Never 
smoked 
16 71.0 225.5 (138.1-
368.1) 
1.00 1.00 
 Ex-smoker 35 167.9 208.5 (149.7-
290.4) 
0.90 (0.50-1.62) 0.91 (0.49-1.69) 
 Current 
smoker 
5 21.6 231.7 (96.4-
556.6) 
1.19 (0.44-3.27) 
p =0.966 
1.17 (0.41-3.28) 
p =0.943 
Highly 
sensitive CRP 
(mg/ml) 
<1 4 22.9 174.8 (65.6-
465.6) 
1.00 1.00 
 1-3  17 57.9 293.6 (182.5-
472.3) 
1.42 (0.48-4.25) 1.31 (0.43-3.94) 
 >3  32 174.7 183.1 (129.5-
259.0) 
1.03 (0.37-2.92) 
p =0.904 
0.98 (0.34-2.80) 
p=0.95 
   ~Hazards ratios adjusted for a prothrombotic state          %Hazards ratios adjusted for age, sex and a prothrombotic state                  
 
 
Figure 2:  Kaplan-Meier plot of survival amongst individuals with IPF with and without a prothrombotic 
state 
 
 
 
Discussion 
In this large population based study, we found that a prothrombotic state was almost five times more 
common in people with IPF compared to general population controls. People with IPF were also more 
likely to have multiple clotting defects. We also found that a prothrombotic state is associated with 
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disease severity at diagnosis measured by pulmonary function indices, and carries a three-fold 
increase in mortality. 
 The main strength of our study is its large size of well phenotyped individuals with IPF and the ability 
to study the association with individual clotting defects. Cases were recruited from specialist centres 
and district general hospitals which enabled us to capture the full spectrum of patients with IPF and 
avoid sampling bias that occurs with studies conducted only at tertiary referral centres. We are 
confident of the diagnosis of IPF within our cohort as all HRCT scans were reviewed by two thoracic 
radiologists who are part of the regional interstitial lung disease multidisciplinary team, and cases 
were stratified into definite or probable UIP based in the ATS/ERS diagnostic criteria for diagnosis of 
IPF.[18] Furthermore, we have previously shown good inter-observer agreement (К=0.67) between 
these two thoracic radiologists.[19]   The age distribution and survival of individuals with IPF in our 
study is similar to other population based cohorts of IPF, [20-24] reassuring us of the robust diagnosis 
of IPF and making our findings generalizable. Our main exposure was a prothrombotic state confirmed 
on laboratory testing, ensuring that there was no recall bias. Furthermore, using the higher baseline 
value of levels greater than 165 IU/dL as our definition of elevated Factor VIII reduced the possibility 
of misclassification of a procoagulant state in this older population.  As we only included incident cases 
of IPF, the findings from our cohort analysis are unlikely to be due to survival bias. In addition to this, 
the detail of information collected enabled us to explore and adjust for various confounding factors 
including systemic inflammation and investigate the possibility of effect modification.  
Although our data are robust, this study did have a number of factors that need consideration. Only 5 
out of 306 (1.6%) in our cohort of people with physician diagnosed IPF underwent a lung biopsy, which 
is in keeping with current clinical practice in the United Kingdom, making our data generalizable to 
this population, but less so to other studies that used a histological diagnosis of UIP. However, current 
evidence suggests a high specificity for the diagnosis of IPF made on HRCT scanning in comparison to 
surgical lung biopsy,[24-27] making it likely that any diagnostic imprecision, if present, is minimal.  In 
the subgroup of 110 people with definite UIP on HRCT, the risk of having a prothrombotic state 
compared to general population controls was markedly increased. Furthermore, a study by Fell and 
colleagues has suggested that age is a strong predictive factor of IPF in people with an atypical UIP 
radiological appearance, whereby individuals over the age of 65 years had 89% specificity for 
confirming IPF by surgical lung biopsy.[23] For the subgroup of cases in our study with probable UIP 
(n=101) approximately 85% were over the age of 65, reassuring us that actually the majority of these 
cases have a high certainty of having UIP. The boundaries between the disease entities such as UIP 
and NSIP within lung fibrosis still remain unclear,[23] and this is highlighted by studies showing that 
familial IPF has a wide clinical phenotype ,[28] and that people may have different histological findings 
in different regions of their lungs.[24]  This may explain why our findings indicate that people with 
fibrotic NSIP and unclassifiable lung disease also have an increased tendency to clot.   
Another factor for consideration is that some of the coagulation proteases and markers of clotting 
dysfunction also act as acute phase response proteins, raising the possibility that some of our findings 
could be attributed to inflammation or inter-current infection. However, after adjustment with hsCRP, 
there was still a strong association that a prothrombotic state was more common in people with IPF 
compared to controls, and is unlikely due to residual confounding. Our main exposure variable is a 
prothrombotic state, as defined by the British Committee for Standards in Haematology.[13] This was 
a composite binary variable defined as having at least one inherited or acquired clotting abnormality, 
assuming each coagulopathy to have an equal effect on the pro-thrombotic state. However, although 
this approach is useful from a statistical perspective, it needs to be considered that different 
coagulopathies may vary in magnitudes of clotting tendency. 
. The number of deaths in our IPF cohort is high given the short follow up period, but our cumulative 
survival estimates are similar to other observational IPF studies, [20-22, 24] and show a significant 
difference in survival in people with IPF with and without a prothrombotic state.  Our study found no 
association between survival in people with IPF and being currently on warfarin. However, given the 
small number of deaths in the cohort and lack of statistical power to address this question, no firm 
conclusions can be drawn.  
We used people from the general population without a diagnosis of IPF as our control group as this is 
a representative sample of individuals without IPF taken from the population from which the cases 
arose. Because all people with IPF are diagnosed in hospital, the risk of selection bias by recruiting 
controls from primary care centres is minimal. Although the response rate from our controls was 
substantially  lower than the cases (28% vs. 86%), we believe that our findings are representative of 
the general population, as potential controls approached were not aware of the hypothesis tested or 
of their individual thrombotic state.   
The final number of cases with definite or probable UIP (n=211) included in the final analyses falls 
slightly short of the sample size estimated by the power calculation (n=244). However, this was on the 
assumption that a prothrombotic state would be present in 20% of the controls. We found that the 
prevalence of a prothrombotic state was significantly higher in our controls (46.5%), therefore 
providing us to have adequate power with a reduced sample size.  
To our knowledge, this is the first population-based study to investigate the association between a 
prothrombotic state and IPF.  Whilst the findings of our study confirm this association, it does not 
establish causality. Possible explanations for our findings include a prothrombotic state being a risk 
factor for developing IPF or the possibility that IPF leads to the development of a prothrombotic state 
or that they share risk factors. The findings of this study are consistent with epidemiological and 
laboratory studies suggesting that activation of the coagulation cascade within the lung may be 
involved in the pathogenesis of IPF. Using a large UK primary care database, we previously 
demonstrated that people with IPF were more likely to have a venous thrombo-embolic event (VTE) 
compared to controls, even in the time period before the diagnosis of IPF was made [8] and this 
observation is supported by our data from the current study where current anticoagulant therapy and 
coronary heart disease were associated with IPF. More recently, a study using registered death 
certificates in the USA showed that thrombo-embolic events were higher in people with pulmonary 
fibrosis compared to people with a chronic obstructive pulmonary disease (COPD), lung cancer and 
the general population.[10] Furthermore, this study also suggested that individuals with pulmonary 
fibrosis and a VTE died at a younger age than those with pulmonary fibrosis alone.[10] Using a large 
registry of Danish patients, Sode and colleagues found that the risk of developing idiopathic interstitial 
pneumonia (IIP) was higher in people who had previously had a VTE, and this risk was highest amongst 
the subset of people who had not received anticoagulant treatment.[9]  
Further evidence that the clotting cascade is involved in the aetiology of IPF comes from laboratory 
studies and animal models. In vivo studies have shown that fibrinolytic activity is suppressed within 
lungs of people with IPF, resulting in fibrin deposition in the interstitial and alveolar spaces,[29] and 
there is evidence of high levels of tissue factor in broncho-alveolar lavage (BAL) fluid of people with 
IPF[30] as well as over expression of plasminogen activator inhibitor-1 (PAI-1) in type 2 pneumocytes 
within honeycomb lesions,[31] all of which may increase local fibrin deposition.  Patient studies and 
animal models of fibrotic lung disease also support the role of thrombin, which plays a central role in 
the final common pathway of the clotting cascade, in activating protease-activated receptor type 1 
(PAR-1) expressed  in lung tissue.[32-34] Studies have demonstrated that PAR-1 is highly expressed on 
cells implicated in fibrosis in the lungs of people with IPF, [32] suggesting the receptor plays an 
important role in the pathogenic process. Activation of PAR-1 receptorsleads to the induction and 
release of potent pro-fibrotic[35] and pro-inflammatory mediators,[5]induces differentiation of 
fibroblasts to myofibroblasts[36] and promotes extracellular matrix protein production.[37] 
Furthermore, active inhibition of the clotting cascade using nebulized heparin, urokinase or activated 
protein C reduces collagen accumulation and the development of fibrotic lesions in experimental 
models of lung fibrosis.[38, 39] 
There have been mixed results of clinical trials using anticoagulants as potential treatments for IPF.  A 
clinical trial in Japan using warfarin and corticosteroids or corticosteroids alone in individuals with 
progressive IPF indicated that anticoagulation may prolong survival.[11] This is different to the findings 
of the anticoagulant effectiveness in idiopathic pulmonary fibrosis (ACE-IPF) trial which was stopped 
due to an excessive number of deaths in the warfarin arm (14 warfarin vs. 3 placebo; p=0.005).  The 
majority of deaths in the warfarin arm were due to respiratory failure,[12] suggesting that 
manipulation of the clotting cascade with warfarin may lead to acceleration of lung fibrosis. Whilst 
disappointing, this provides  further evidence that the clotting cascade may be central to the disease 
process in IPF, and that the coagulation cascade remains a valid therapeutic target in IPF. 
In summary, our findings suggest that people with IPF are more than four times more likely to have a 
prothrombotic state and almost six times more likely to have two or more clotting defects compared 
to general population controls. The increased tendency to clot is also associated with disease severity 
at presentation and increases mortality by three-fold amongst people with IPF. These findings 
demonstrate strong differences in clotting dysfunction and firmly establish the clotting cascade at the 
centre of aetiology and prognosis in IPF. Studies from animal models have suggested that 
manipulation of the clotting cascade can alter the course of fibrosis, raising the possibility that 
manipulation of the clotting cascade could be an important treatment avenue for people with IPF. 
However, the recent placebo-controlled trial of warfarin in IPF has demonstrated that broad-spectrum 
anticoagulation may not be the answer, and further mechanistic work into how best to manipulate 
the clotting cascade to improve the outlook for people with IPF is warranted. 
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